Evidence grows for continued jabs to combat COVID-19 mortality

The risk of death from COVID-19 decreases significantly after vaccination but this protection diminishes after six months, providing evidence for continued booster doses, a new study has found.

Researchers from the UK Health Security Agency (UKHSA) analysed more than 10 million cases of COVID-19 in adults between May 2020 and February 2022. Their findings are published in the Journal of the Royal Society of Medicine (JRSM).

The Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was cross-referenced with vaccination status, revealing a clear association between vaccination and reduced mortality. Notably, the study highlights a crucial timeframe - within six months of the last vaccine dose - when CFR was consistently at its lowest across all age groups. After this, the protective benefit began to wane and CFR increased.

The research underscores the success of the COVID-19 vaccination program in reducing mortality rates.

Among adults over 50, CFR was 10 times higher in the unvaccinated (6.3%) compared to those who had been vaccinated within six months prior to testing positive (0.6%). The study also reveals a steep decline in CFR in early 2021, aligning with the initial vaccine rollout.

COVID-19 Case Fatality Risk reduced after vaccination, with the lowest seen across all age bands when vaccinated up to six months prior to the specimen date. This provides some evidence for continued booster doses in older age groups."

Florence Halford from the UKHSA's COVID-19 Vaccines and Epidemiology Division

Source:
Journal reference:

Halford, F., et al. (2023). Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study. Journal of the Royal Society of Medicine. doi.org/10.1177/01410768231216332.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
WHO grants Emergency Use Listing for LC16m8 mpox vaccine